Showing 1,523 results

Filters Content type: News, Editors' picks Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

PrEP

Finns buying HIV prevention drugs from Germany because they're cheaper

Editor's pick
YLE
30 June 2018
Behaviour change interventions

“I’m on the Pill” PrEP Ads Begin Airing on National TV

Editor's pick
Poz
29 June 2018
New & experimental HIV treatments

European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

Editor's pick
Gilead press release
25 June 2018
Pharmaceutical industry

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

Editor's pick
Reuters
25 June 2018
Pharmaceutical industry

Glaxo Venture's Lofty Goal in HIV: Eclipse Gilead as Top Player

Editor's pick
Bloomberg
21 June 2018
PrEP

#BREAKTHEPATENT

Editor's pick
breakthepatent.org
20 June 2018
New & experimental HIV treatments

GSK's two-drug HIV treatment meets main goal in late stage studies

Editor's pick
Reuters
15 June 2018
PrEP

With TV ads, drugmaker Gilead brings HIV prevention drug out of the closet

Editor's pick
NBC News
31 May 2018
Generic medicines

EU makes it easier for companies to produce generic medicines for export

Editor's pick
Reuters
29 May 2018
Pharmaceutical industry

AIDS Healthcare Foundation files two lawsuits against Gilead

Editor's pick
The Bay Area Reporter
21 May 2018
Access to healthcare

Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents

Editor's pick
Intellectual Property Watch
14 May 2018
Side effects

Is Gilead’s Entire HIV Enterprise Built on a False Promise?

Editor's pick
Poz
10 May 2018
Pharmaceutical industry

Will the European Court of Justice put a stop to the evergreening of Truvada patents?

Editor's pick
Medicines Law & Policy
9 May 2018
Pharmaceutical industry

Patients sue Gilead, saying drug company intentionally delayed safer HIV medicine

Editor's pick
Los Angeles Times
9 May 2018
Access to healthcare

Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition

Editor's pick
Intellectual Property Watch
9 May 2018
Pharmaceutical industry

Major Win for Patients as Brazil Rejects A Key Patent on Gilead Hepatitis C Drug and European Union Denies Patent Extension to Gilead’s HIV Drug

Editor's pick
I-MAK
8 May 2018
Pharmaceutical industry

Gilead Topples As Its Hepatitis C Drug Franchise Continues To Crumble

Editor's pick
Investor's Business Daily
2 May 2018
Pharmaceutical industry

GlaxoSmithKline's next-generation HIV battle against Gilead is already taking a toll on growth

Editor's pick
FiercePharma
30 April 2018
New & experimental HIV treatments

European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)

Editor's pick
Gilead press release
27 April 2018
Pharmaceutical industry

Patient Advocacy Groups Take In Millions From Drugmakers. Is There A Payback?

Editor's pick
Washington Post
10 April 2018
Clinical trials

My PrEP story: Patrick (part 2)

Editor's pick
Prepster
10 April 2018
Pharmaceutical industry

Why do new medicines cost so much, and what can we do about it?

Editor's pick
The Guardian
10 April 2018
Pharmaceutical industry

A Cheaper Version of Truvada Is Hitting the US Market: Here's Why It Might Not Lower Costs

Editor's pick
The Body
4 April 2018
Pharmaceutical industry

Mylan Introduces Symfi™ Triple Combo Once-Daily HIV Treatment in the U.S.

Editor's pick
Mylan press release
3 April 2018